Compare RVMD & MLM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RVMD | MLM |
|---|---|---|
| Founded | 2014 | 1993 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Mining & Quarrying of Nonmetallic Minerals (No Fuels) |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 40.3B | 34.4B |
| IPO Year | 2020 | 1996 |
| Metric | RVMD | MLM |
|---|---|---|
| Price | $193.42 | $470.96 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 24 | 24 |
| Target Price | $259.14 | ★ $633.92 |
| AVG Volume (30 Days) | ★ 2.2M | 728.5K |
| Earning Date | 11-04-2026 | 11-03-2026 |
| Dividend Yield | N/A | ★ 0.71% |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ 29.27 |
| Revenue | N/A | ★ $6,150,000,000.00 |
| Revenue This Year | N/A | $27.17 |
| Revenue Next Year | $564.95 | $23.04 |
| P/E Ratio | ★ N/A | $16.14 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $49.05 | $470.19 |
| 52 Week High | $224.31 | $710.97 |
| Indicator | RVMD | MLM |
|---|---|---|
| Relative Strength Index (RSI) | 44.06 | 34.56 |
| Support Level | $188.18 | $470.19 |
| Resistance Level | $194.19 | $636.33 |
| Average True Range (ATR) | 8.63 | 10.75 |
| MACD | -1.27 | 0.42 |
| Stochastic Oscillator | 41.68 | 19.64 |
Revolution Medicines Inc is a clinical-stage precision oncology company developing novel targeted therapies for RAS-addicted cancers. The Company possesses structure-based drug discovery capabilities built upon chemical biology and cancer pharmacology know-how and proprietary technologies that enable the creation of small molecules tailored to unconventional binding sites. Its research and development pipeline comprises inhibitors that bind directly to RAS variants (RAS(ON) Inhibitors), designed to be used as monotherapy, in combination with other RAS(ON) Inhibitors and/or other therapeutic agents.
Martin Marietta is a leading US producer of construction aggregates, having produced roughly 200 million tons in 2025. Its aggregate reserves represent approximately 85 years of supply at 2025 production levels. Over the past several years, the company has increased its exposure to aggregates while reducing its presence in cement and downstream businesses such as concrete and asphalt. More recently, Martin Marietta expanded into an aggregate-adjacent business through its acquisition of Lhoist North America, the largest US producer of lime. The company operates across 28 states, with smaller operations in Canada and the Bahamas.